QuickBird Medical
  • Case Studies
    • Case Studies
    • Customers
  • Services
    • Development: DiGA
    • Development: Medical Software – EU & MDR
    • Development: Medical Software – US & FDA
    • Development: Health Apps
    • Development: Wearables for Medical Devices
    • Development: Decision Support Systems
    • Development: Medical AI Systems
    • Legal Manufacturer for Medical Devices
    • BSI TR-03161 for DiGA
    • ePA & Health ID for DiGA
    • Further Services
  • Insights
  • Team
  • Jobs
  • Contact
  • German
Select Page
AI Act: Guidelines for medical device manufacturers according to MDR (2025)

AI Act: Guidelines for medical device manufacturers according to MDR (2025)

by Alexander Fenkiw | Jan 31, 2025 | medical-software-whitepaper

The EU is now also regulating the use of artificial intelligence (AI) with the EU AI Act. This also affects manufacturers of software medical devices that integrate AI into their MDR medical devices. The AI Act is intended to ensure that AI systems are designed in a...
MDR Risk Class I vs. IIa: Differences for software medical devices

MDR Risk Class I vs. IIa: Differences for software medical devices

by Alexander Fenkiw | Jan 9, 2025 | medical-software-whitepaper, Unkategorisiert

At the beginning of the development of a software medical device, the central question is: Which risk class applies to my product? Risk classification has serious implications and significantly influences the cost and time frame of product development. In extreme...
Phrasing of the intended use for (software) medical devices

Phrasing of the intended use for (software) medical devices

by Alexander Fenkiw | Sep 10, 2024 | medical-software-whitepaper

How do I actually decide whether my product is a medical device? Where do I start when I want to determine its risk class? And what statements can I use to promote my product in the end? The answers to these and many other questions can be answered on the basis of...
DiGA price negotiations with the GKV-Spitzenverband

DiGA price negotiations with the GKV-Spitzenverband

by Alexander Fenkiw | Mar 17, 2024 | diga-whitepaper

The development of a digital health application (DiGA) costs time and money and involves many regulatory hurdles. As a manufacturer, you naturally have an interest in ensuring that this effort pays off in the end. You probably already know that even if your...
Interoperability for digital health applications (DiGA)

Interoperability for digital health applications (DiGA)

by Alexander Fenkiw | Mar 17, 2024 | diga-whitepaper, Unkategorisiert

We would like to quickly introduce the topic of interoperability in DiGA development with a small example: “Μια DiGA πρέπει να πληροί ορισμένες απαιτήσεις διαλειτουργικότητας.” Do you understand this sentence? Unless you speak Greek, probably not. You therefore need...
« Older Entries
Next Entries »

Insider-Empfehlungen für DiGA-Hersteller in 2025
Downloaden Sie jetzt unser Whitepaper

Insider-Empfehlungen für Software-Medizinprodukt-Hersteller in 2025
Downloaden Sie jetzt unser Whitepaper


Sie planen eine Medical Software oder DiGA?

Sprechen Sie mit unserem Geschäftsführer Malte Bucksch

+49 (0) 89 54998380
kontakt@quickbirdmedical.com

Are you planning to develop medical software or a digital health application?

Speak with our managing director, Malte Bucksch

+49 (0) 89 54998380
contact@quickbirdmedical.com
Kontakt

+49 (0) 89 54998380
kontakt@quickbirdmedical.com

 

Whitepaper

13 wichtige Empfehlungen für angehende DiGA-Hersteller 2025

13 wichtige Empfehlungen für angehende Medizinprodukt-Hersteller 2025

Aktuelles

DiGA- und Medical Software-Newsletter

Digital Health Events 2025

Presse – QuickBird in den Medien

© 2025 Impressum | Datenschutz